Olanzapine augments the effect of selective serotonin reuptake inhibitors by suppressing GABAergic inhibition via antagonism of 5-HT6 receptors in the dorsal raphe nucleus

Neuropharmacology

Volumn 95, Issue , 2015, Pages 261-268

  Asaoka, Nozomi ^a   Nagayasu, Kazuki ^a,b   Nishitani, Naoya ^a   Yamashiro, Mayumi ^a   Shirakawa, Hisashi ^a   Nakagawa, Takayuki ^a,c   Kaneko, Shuji ^a  

^a KYOTO UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

5 HT6 receptor; Depression; GABAergic neurons; Olanzapine; Selective serotonin reuptake inhibitor; Serotonergic neurons

Indexed keywords

6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; BICUCULLINE; CITALOPRAM; FLUOXETINE; KETANSERIN; N (3,5 DICHLORO 2 METHOXYPHENYL) 4 METHOXY 3 (1 PIPERAZINYL)BENZENESULFONAMIDE; OLANZAPINE; SEROTONIN 6 RECEPTOR; 4 AMINOBUTYRIC ACID A RECEPTOR BLOCKING AGENT; 4 AMINOBUTYRIC ACID RECEPTOR; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; PIPERAZINE DERIVATIVE; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SULFONAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; BRAIN CELL CULTURE; BRAIN SLICE; CONCENTRATION RESPONSE; DORSAL RAPHE NUCLEUS; DRUG ANTAGONISM; DRUG POTENTIATION; ELECTROPHYSIOLOGY; FEMALE; GABAERGIC SYSTEM; GABAERGIC TRANSMISSION; MALE; MOUSE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; RAT; TAIL SUSPENSION TEST; ANIMAL; C57BL MOUSE; DEPRESSIVE DISORDER; DISEASE MODEL; DRUG EFFECTS; METABOLISM; NERVE CELL INHIBITION; PHYSIOLOGY; SEROTONINERGIC NERVE CELL; TISSUE CULTURE TECHNIQUE; WISTAR RAT;

ANIMALS; ANTIDEPRESSIVE AGENTS; BENZODIAZEPINES; BICUCULLINE; CITALOPRAM; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; DORSAL RAPHE NUCLEUS; FEMALE; FLUOXETINE; GABA-A RECEPTOR ANTAGONISTS; GABAERGIC NEURONS; MALE; MICE, INBRED C57BL; NEURAL INHIBITION; PIPERAZINES; RATS, WISTAR; RECEPTORS, SEROTONIN; SEROTONERGIC NEURONS; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS; SULFONAMIDES; TISSUE CULTURE TECHNIQUES;

EID: 84928402444     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2015.03.032     Document Type: Article

References (55)

1. G.K. Aghajanian, and R.Y. Wang Habenular and other midbrain raphe afferents demonstrated by a modified retrograde tracing technique Brain Res. 122 1977 229 242
2. M. Amargós-Bosch, A. Adell, and F. Artigas Antipsychotic drugs reverse the AMPA receptor-stimulated release of 5-HT in the medial prefrontal cortex J. Neurochem. 102 2007 550 561
3. J.L. Andersson, G.G. Nomikos, M. Marcus, P. Hertel, J.M. Mathé, and T.H. Svensson Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectively in the mesolimbic dopaminergic system Naunyn Schmiedeb. Arch. Pharmacol. 352 1995 374 385
4. S.J. Bang, and K.G. Commons Forebrain GABAergic projections from the dorsal raphe nucleus identified by using GAD67-GFP knock-in mice J. Comp. Neurol. 520 2012 4157 4167
5. R.H. Belmaker, and G. Agam Major depressive disorder N. Engl. J. Med. 358 2008 55 68
6. C.L. Bergner, A.N. Smolinsky, P.C. Hart, B.D. Dufour, R.J. Egan, J.L. Laporte, and A.V. Kalueff Mouse models for studying depression-like states and antidepressant drugs Methods Mol. Biol. 602 2010 267 282
7. 6 agonists Bioorg. Med. Chem. 17 2009 5153 5163
8. 2 receptor antagonists using in vivo microdialysis Neuropharmacology 50 2006 726 732
9. 1A receptor-mediated feedback: a microdialysis study in the amygdala J. Neurochem. 76 2001 1645 1653
10. 6 receptors by olanzapine Eur. J. Pharmacol. 430 2001 341 349
11. 1-adrenergic receptors in vitro Schizophr. Res. 37 1999 107 122
12. A.F. Carvalho, M. Berk, T.N. Hyphantis, and R.S. McIntyre The integrative management of treatment-resistant depression: a comprehensive review and perspectives Psychother. Psychosom. 83 2014 70 88
13. C. Challis, J. Boulden, A. Veerakumar, J. Espallergues, F.M. Vassoler, R.C. Pierce, S.G. Beck, and O. Berton Raphe GABAergic neurons mediate the acquisition of avoidance after social defeat J. Neurosci. 33 2013 13978 13988
14. 1A receptor activation in rat dorsal raphe nucleus and hippocampus in vitro J. Pharmacol. Exp. Ther. 315 2005 109 117
15. S.A. Corya, D. Williamson, T.M. Sanger, S.D. Briggs, M. Case, and G. Tollefson A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression Depress. Anxiety 23 2006 364 372
16. S. Dubé, G.D. Tollefson, M.E. Thase, S.D. Briggs, L.E. Van Campen, M. Case, and M. Tohen Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depression Bipolar. Disord. 9 2007 618 627
17. S.E. Gartside, A.J. Cole, A.P. Williams, R. McQuade, and S.J. Judge AMPA and NMDA receptor regulation of firing activity in 5-HT neurons of the dorsal and median raphe nuclei Eur. J. Neurosci. 25 2007 3001 3008
18. C. Gérard, S. el Mestikawy, C. Lebrand, J. Adrien, M. Ruat, E. Traiffort, M. Hamon, and M.P. Martres Quantitative RT-PCR distribution of serotonin 5-HT6 receptor mRNA in the central nervous system of control or 5,7-dihydroxytryptamine-treated rats Synapse 23 1996 164 173
19. 6 receptor-like material in the rat central nervous system Brain Res. 746 1997 207 219
20. S.E. Hammack, M.A. Cooper, and K.R. Lezak Overlapping neurobiology of learned helplessness and conditioned defeat: implications for PTSD and mood disorders Neuropharmacology 62 2012 565 575
21. M. Higuchi, Y. Suzuki, Y. Yatani, Y. Kitagawa, K. Nagayasu, H. Shirakawa, T. Nakagawa, and S. Kaneko Augmentation of serotonin release by sustained exposure to 3,4-methylenedioxymethamphetamine and methamphetamine in rat organotypic mesencephalic slice cultures containing raphe serotonergic neurons J. Neurochem. 106 2008 2410 2420
22. 6 antagonists in the rat forced swimming test: potential therapeutic utility in mood disorders associated with Alzheimer's disease Life Sci. 84 2009 558 562
23. K. Kamiń, K. Gołembiowska, and Z. Rogóż Effect of risperidone on the fluoxetine-induced changes in extracellular dopamine, serotonin and noradrenaline in the rat frontal cortex Pharmacol. Rep. 65 2013 1144 1151
24. A. Khan, S.R. Khan, J. Hobus, J. Faucett, V. Mehra, E.L. Giller, and R.L. Rudolph Differential pattern of response in mood symptoms and suicide risk measures in severely ill depressed patients assigned to citalopram with placebo or citalopram combined with lithium: role of lithium levels J. Psychiatr. Res. 45 2011 1489 1496
25. 6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation-an effect sensitive to NMDA receptor antagonism Neuropharmacology 47 2004 195 204
26. S. Koch, K.W. Perry, and F.P. Bymaster Brain region and dose effects of an olanzapine/fluoxetine combination on extracellular monoamine concentrations in the rat Neuropharmacology 46 2004 232 242
27. 2 receptors activate local GABA inhibitory inputs to serotonergic neurons of the dorsal raphe nucleus Brain Res. 873 2000 34 45
28. 2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders Neuropsychopharmacology 28 2003 402 412
29. 2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine Neuropsychopharmacology 30 2005 2205 2215
30. R. Martín-Ruiz, M.V. Puig, P. Celada, D.A. Shapiro, B.L. Roth, G. Mengod, and F. Artigas Control of serotonergic function in medial prefrontal cortex by serotonin-2A receptors through a glutamate-dependent mechanism J. Neurosci. 21 2001 9856 9866
31. A. McIntyre, A. Gendron, and A. McIntyre Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study Depress. Anxiety 24 2007 487 494
32. K.A. Michelsen, J. Prickaerts, and H.W. Steinbusch The dorsal raphe nucleus and serotonin: implications for neuroplasticity linked to major depression and Alzheimer's disease Prog. Brain Res. 172 2008 233 264
33. B.H. Miller, L.E. Schultz, A. Gulati, A.I. Su, and M.T. Pletcher Phenotypic characterization of a genetically diverse panel of mice for behavioral despair and anxiety PLoS One 5 2010 e14458
34. T. Mitsumori, T. Furuyashiki, T. Momiyama, A. Nishi, T. Shuto, T. Hayakawa, F. Ushikubi, S. Kitaoka, T. Aoki, H. Inoue, T. Matsuoka, and S. Narumiya Thromboxane receptor activation enhances striatal dopamine release, leading to suppression of GABAergic transmission and enhanced sugar intake Eur. J. Neurosci. 34 2011 594 604
35. K. Nagayasu, M. Kitaichi, N. Nishitani, N. Asaoka, H. Shirakawa, T. Nakagawa, and S. Kaneko Chronic effects of antidepressants on serotonin release in rat raphe slice cultures: high potency of milnacipran in the augmentation of serotonin release Int. J. Neuropsychopharmacol. 16 2013 2295 2306
36. K. Nagayasu, M. Kitaichi, H. Shirakawa, T. Nakagawa, and S. Kaneko Sustained exposure to 3,4-methylenedioxymethamphetamine induces the augmentation of exocytotic serotonin release in rat organotypic raphe slice cultures J. Pharmacol. Sci. 113 2010 197 201
37. K. Nagayasu, Y. Yatani, M. Kitaichi, Y. Kitagawa, H. Shirakawa, T. Nakagawa, and S. Kaneko Utility of organotypic raphe slice cultures to investigate the effects of sustained exposure to selective serotonin reuptake inhibitors on serotonin release Br. J. Pharmacol. 161 2010 1527 1541
38. J.C. Nelson, and G.I. Papakostas Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials Am. J. Psychiatry 166 2009 980 991
39. N. Nishitani, K. Nagayasu, N. Asaoka, M. Yamashiro, H. Shirakawa, T. Nakagawa, and S. Kaneko Raphe AMPA receptors and nicotinic acetylcholine receptors mediate ketamine-induced serotonin release in the rat prefrontal cortex Int. J. Neuropsychopharmacol. 17 2014 1321 1326
40. 2C receptors Mol. Brain Res. 23 1994 163 178
41. 125I]SB-258585 Brain Res. 934 2002 49 57
42. 6 receptor agonists: WAY-181187 and WAY-208466 Neuropsychopharmacology 33 2008 1323 1335
43. 6 receptor antagonist RO4368554 in rat models for cognition and sensorimotor gating Eur. Neuropsychopharmacol. 17 2007 277 288
44. 2 receptor agonists and antagonists Neuropharmacology 30 1991 1269 1274
45. H. Shikanai, T. Yoshida, K. Konno, M. Yamasaki, T. Izumi, Y. Ohmura, M. Watanabe, and M. Yoshioka Distinct neurochemical and functional properties of GAD67-containing 5-HT neurons in the rat dorsal raphe nucleus J. Neurosci. 32 2012 14415 14426
46. 6 receptor stimulation J. Neurosci. 27 2007 4201 4209
47. F.M. Theisen, M. Haberhausen, M.A. Firnges, P. Gregory, J.H. Reinders, H. Remschmidt, J. Hebebrand, and J. Antel No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation Pharmacogenomics J. 7 2007 275 281
48. M. Tohen, E. Vieta, J. Calabrese, T.A. Ketter, G. Sachs, C. Bowden, P.B. Mitchell, F. Centorrino, R. Risser, R.W. Baker, A.R. Evans, K. Beymer, S. Dube, G.D. Tollefson, and A. Breier Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression Arch. Gen. Psychiatry 60 2003 1079 1088
49. K.M. Tye, J.J. Mirzabekov, M.R. Warden, E.A. Ferenczi, H.C. Tsai, J. Finkelstein, S.Y. Kim, A. Adhikari, K.R. Thompson, A.S. Andalman, L.A. Gunaydin, I.B. Witten, and K. Deisseroth Dopamine neurons modulate neural encoding and expression of depression-related behavior Nature 493 2013 537 541
50. G. Wegener, K. Linnet, R. Rosenberg, and A. Mørk The effect of acute citalopram on extracellular 5-HT levels is not augmented by lithium: an in vivo microdialysis study Brain Res. 871 2000 338 342
51. 6 receptor antagonist SB-399885 in animal models of anxiety and depression Neuropharmacology 52 2007 1274 1283
52. R. Whale, T. Terao, P. Cowen, N. Freemantle, and J. Geddes Pindolol augmentation of serotonin reuptake inhibitors for the treatment of depressive disorder: a systematic review J. Psychopharmacol. 24 2010 513 520
53. 6 receptors in retention of spatial learning in the Morris water maze Neuropharmacology 41 2001 210 219
54. 2 receptor subtype mRNAs in rat brain J. Comp. Neurol. 351 1995 357 373
55. W. Zhang, K.W. Perry, D.T. Wong, B.D. Potts, J. Bao, G.D. Tollefson, and F.P. Bymaster Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex Neuropsychopharmacol 23 2000 250 262